Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Progress in development of NPS's R-568

Oct. 11, 1996

Future metabolic agents in the Yamanouchi pipeline

Oct. 11, 1996

ProScript and Roche to develop compounds for cachexia

Oct. 11, 1996

Appetite-suppressing effects of urocortin

Oct. 11, 1996

Pravastatin continues to demonstrate clinical utility in various patient groups

Oct. 11, 1996

Generic cholestyramine cleared by FDA

Oct. 11, 1996

New hypocholesterolemic agent from Schering-Plough

Oct. 11, 1996

Second Hedgehog-based research collaboration for Ontogeny

Oct. 11, 1996

New introduction for fertility hormone

Oct. 4, 1996

Novo Nordisk and Schering AG sign collaborative agreement for fertility drugs

Oct. 4, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...